Journals / The Anatolian Journal of Cardiology / 2020 / Cilt: 23 - Sayı: 3

Molecular diagnosis methods in familial hypercholesterolemia

Pages
120–127
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review article details different genetic techniques that can be used in FH identification when there is a clinical FH suspicion based on criteria comprised in prognosis scores, knowing that none of these are exhaustive inthe diagnosis, yet they efficaciously overlap and complement each other for confirming the disease at the molecular level. (Anatol J Cardiol2020; 23: 120-7)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Familial hypercholesterolemia (FH) is considered the genetic cause of coronary heart disease and ischemic stroke.
📊
Key Findings & Data:FH is mainly an autosomalcodominant pattern-based disorder and is primarily determined by point mutations within the low-density lipoprotein receptor, apolipoprotein B, and proprotein convertase subtilisin/kexin type 9 genes, causing increased low-density lipoprotein cholesterol levels in the serum ofuntreated individuals.
💡
Conclusion & Impact:This review article details different genetic techniques that can be used in FH identification when there is a clinical FH suspicion based on criteria comprised in prognosis scores, knowing that none of these are exhaustive inthe diagnosis, yet they efficaciously overlap and complement each other for confirming the disease at the molecular level. (Anatol J Cardiol2020; 23: 120-7)
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Familial hypercholesterolemia (FH) is considered the genetic cause of coronary heart disease and ischemic stroke. FH is mainly an autosomalcodominant pattern-based disorder and is primarily determined by point mutations within the low-density lipoprotein receptor, apolipoprotein B, and proprotein convertase subtilisin/kexin type 9 genes, causing increased low-density lipoprotein cholesterol levels in the serum ofuntreated individuals. The accumulation will eventually lead to atherosclerotic cardiovascular disease. Although clinical criteria comprising several prognosis scores, such as the Simon Broome, Dutch Lipid Clinic Network, Make Early Diagnosis to Prevent Early Death, andthe recently proposed Montreal-FH-SCORE, are the conventional basis of diagnosing FH, the genetic diagnosis made by single nucleotidepolymorphism genotyping, multiplex ligation-dependent probe amplification analysis, and sequencing (both Sanger and Next-Generation sequencing) offers unequivocal diagnosis. Given the heterogeneity of known mutations, the genetic diagnosis of FH is often difficult to establish,despite the growing evidence of the causative mutations, as well as the polygenic aspect of this pathology and the importance of cascadescreening of the FH patient’s healthy family members. This review article details different genetic techniques that can be used in FH identification when there is a clinical FH suspicion based on criteria comprised in prognosis scores, knowing that none of these are exhaustive inthe diagnosis, yet they efficaciously overlap and complement each other for confirming the disease at the molecular level. (Anatol J Cardiol2020; 23: 120-7)

🔖

Cite This Article

MOLDOVAN, V., BANESCU, C., DOBREANU, M. (2020). Molecular diagnosis methods in familial hypercholesterolemia. The Anatolian Journal of Cardiology, Cilt: 23 - Sayı: 3, 120–127. https://ajindex.com/articles/365232

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. URL; https://omim.org/entry/143890?search=Familial%20hypercho lesterolaemia&highlight=%22familial%20%28hypercholesterolemi a%7Chypercholesterolaemia%29%22%20familial%20hypercholesterolaemia%20hypercholesterolemia 2. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38: 2459-72. 3. Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al.; European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35: 2146-57. 4. Sharifi M, Futema M, Nair D, Humphries SE. Genetic Architecture of Familial Hypercholesterolaemia. Curr Cardiol Rep 2017; 19: 44. 5. Grenkowitz T, Kassner U, Wühle-Demuth M, Salewsky B, Rosada A, Zemojtel T, et al. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia. Atherosclerosis 2016; 253: 88-93. 6. Cameron J, Holla ØL, Ranheim T, Kulseth MA, Berge KE, Leren TP. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet 2006; 15: 1551-8. 7. Wang J, Dron JS, Ban MR, Robinson JF, McIntyre AD, Alazzam M, et al. Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically. Arterioscler Thromb Vasc Biol 2016; 36: 2439-45. 8. Mytilinaiou M, Kyrou I, Khan M, Grammatopoulos DK, Randeva HS. Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management. Front Pharmacol 2018; 9: 707. 9. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al.; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 3478-90a. 10. Do R, Stitziel NO, Won HH, Jørgensen AB, Duga S, Angelica Merlini P, et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 2015; 518: 102-6. 11. Paquette M, Dufour R,